Feed BTAI
BT

BioXcel Therapeutics, Inc.

BTAI · NASDAQ

$0.07 -18.79% (-$0.02)
1M -90.28%
Market Cap $2.28M
P/E Ratio -
Div. Yield -
ROE -
Piotroski F-Score Weak
3/9
Valuation
57 /100
Fair
P/S 3.08x
P/E N/A
EV/EBITDA N/A
Growth
100 /100
Growing
Rev. growth 19.63%
EPS growth N/A
FCF growth N/A
Profitability
18 /100
Weak
Gross margin 45.28%
Net margin 9,549.86%
Op. margin 6,014.42%
Quality
58 /100
Average
ROIC 1,144.58%
ROA 246.05%
Asset turnover 0.03x
Debt
0 /100
High
Current ratio 0.21x
Int. coverage -3.11x
Debt/Equity N/A
Stability
19 /100
Unstable
Beta 0.29x
Rev. volatility 170.96%
EPS volatility 46.04%

Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe

Întreabă StockBot despre BTAI
Online

Despre companie

BioXcel Therapeutics, Inc. (BTAI) is a biotechnology company that focuses on researching and developing new therapeutic approaches using artificial intelligence and data analysis. The company leverages advanced technologies and algorithms to identify and develop drugs for various diseases, including neurological and psychiatric disorders. With an innovative approach to drug development and treatment using artificial intelligence, the shares of BioXcel Therapeutics, Inc. (BTAI) may represent an intriguing investment opportunity for investors interested in biotechnology and medical research.

Nu este încă disponibil în limba dumneavoastră, așa că textul este în engleză.

Sector

Healthcare

Industry

Biotechnology

CEO

Vimal D. Mehta

Employees

29

Headquarters

New Haven

Evenimente viitoare

11 NOV.

Earnings

Upcoming earnings report

50d

Folosim cookie-uri esențiale pentru funcționarea site-ului și cookie-uri analitice opționale pentru a măsura utilizarea. Consultați Politica de confidențialitate.